Oncology

News

Novartis steals a march in CDK4/6 market with breast cancer ...

Novartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in metastatic breast cancer. The results of the MONALEESA-7 trial – reported

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar takes a first look at interim data from t...

Will Erleada take the lead in metastatic CSPC?

ASCO 2019 Live coverage

ASCO 2019 day three

Exclusive live coverage from day three of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, pro

Partner Content

Partner Content

J+D Forecasting - Forecasting in Oncology Online Training

J+D Forecasting - Online Oncology Forecasting Training

News

Epizyme files tazemetostat, seeking first okay in rare cance...

Epizyme has filed for accelerated FDA approval of tazemetostat for advanced epithelioid sarcoma (ES), a rare form of cancer with no approved drugs in the US.

Views & Analysis

how should biotechs harness adaptive trials

Flipping the paradigm – how should biotechs harness adaptive...

Failed clinical trials can be fatal for small biotechs that don’t have the backing of big pharma, and even having to alter plans can be prohibitively costly.